ArticleNutrition research and practice2026
Fermented oyster extract promotes height growth in children with mild short stature: a randomized, double-blind, placebo-controlled trial.
Article in Nutrition research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUNDS/
objectivesChild growth is affected by genetics, nutrition, physical activity, and environmental factors. Despite the improvements in average height among Korean children due to better socioeconomic and nutritional status, safe and effective growth-promoting interventions are still needed for children with mild short stature. This study evaluated the safety and efficacy of fermented oyster extract (FGO) supplementation in children aged 6 to 9 yrs with heights between the third and 25th percentiles for age and gender. SUBJECTS/
methodsIn this randomized, double-blind, placebo-controlled trial, subjects received FGO (n = 40) or placebo (n = 40) once daily (500 mg/day) for 24 weeks. This study evaluated the height growth, bone age (BA), growth hormone (GH), insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3), and urine deoxypyridinoline (DPD) for the efficacy of FGO and sex hormones, including estradiol, luteinizing hormone, and testosterone, for its safety. Finally, 66 children (33 each in the FGO and placebo group) completed the study. No significant baseline differences existed between the 2 groups.
resultsAfter 24 weeks, the FGO group showed significant improvements in height, height SD score, and height velocity (all
conclusionFGO may be a safe and effective health supplement ingredient for height growth in children, irrespective of gender. Future studies will need to evaluate the long-term effects of FGO and its applicability across various populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.